Parikshit Augmented Generation_VC — 2026-03

A March digest of what you added to VC Landscape & News. Themes this month: biotech financing and dealmaking, “AI for bio” platform maturation, and a cluster of essays mapping second-order effects of abundant intelligence and AI platform power.

• Included articles:
  • The unraveling of EQRx's low-cost drug dream
  • Biotech's top money raisers: 2025
  • Sensei Biotherapeutics Announces Acquisition of Faeth Therapeutics and $200 Million Concurrent Private Placement
  • Some Simple Economics of AGI
  • THE 2028 GLOBAL INTELLIGENCE CRISIS
  • Generate Biomedicines S-1/A
  • Incumbents Kill Startups. Sometimes. - by Fabian Hediger
  • Liquid AI and Insilico Release Lightweight On-Premise AI Model for Drug Discovery
  • GRAIN | Barbarians at the barn: private equity sinks its teeth into agriculture
  • The world needs an AI lab — for Data - by Bobby Samuels
  • Scientific Discovery AI Map | Topology Research
  • The US vs. China Manufacturing Debate - YouTube
  • Copper One: The World's Only Autonomy-First Mine & Refinery
  • Eli Lilly reaches deal to bring AI-developed drugs to global market

The unraveling of EQRx's low-cost drug dream

Summary

EQRx tried to build a “low-cost drug” biotech by pairing a pipeline of mostly ex-China assets with a “Global Buyers Club” meant to guarantee demand at lower prices. The effort unraveled when U.S. regulatory requirements (especially around representative trial populations and survival endpoints) raised the cost and timeline, eroding the economic thesis and triggering a long strategic review that ultimately ended in a cash-focused acquisition.

Key points

• Public debut via SPAC at roughly $4.2B valuation; five clinical-stage programs across oncology and immune-inflammatory disease.
• Lead assets included sugemalimab (PD-L1) and aumolertinib (EGFR); FDA pushed for additional Phase 3 evidence in diverse U.S. populations and survival outcomes.
• “No commercially viable path” for sugemalimab in U.S. NSCLC was disclosed; strategy shifted toward market-based pricing for remaining U.S. programs.
• Broad outreach to potential acquirers and partners yielded limited engagement; out-licensing attempts also stalled.
• End state was an acquisition that primarily valued EQRx’s cash, not its pipeline.

So what?

The story is a reminder that “cost disruption” in biotech is often bounded by regulatory and evidentiary requirements. Any thesis that relies on external clinical data or faster/cheaper paths needs an explicit plan for U.S.-grade confirmatory evidence, and a financing plan that survives when timelines extend.

Biotech's top money raisers: 2025

Summary

A look at the largest private biotech financings of 2025, highlighting a market that preferred fewer, larger rounds and later-stage assets. A notable signal is how much capital flowed to obesity/metabolic programs and to AI-native drug discovery platforms.

Key points